• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    LANXESS (XTRA:LXS) Stock Recovery Case Hinges On Losses And Utilization

    Simply Wall St·08/09/2026 04:41:08
    Listen to the news

    LANXESS went into this earnings day priced like a problem stock. The share price closed at €16.43, roughly flat over the past week and down about 11% over three months, even with a small rebound over the last month. The market has been treating the chemicals group as a restructuring story with weak profitability.

    The headline from Q2 is simple. LANXESS is still loss making, with a basic loss per share of €0.62, but the company lifted revenue to €1,561m and cut the quarterly net loss to €53m. For a stock priced on distress, that shift in the income statement is what really matters today.

    Interested in LANXESS as a restructuring story but uneasy about a stock that is still loss making? Check out our list of list of solid balance sheet and fundamentals stocks (422 results).

    Q2 2026 Earnings Summary

    • Revenue, Q2 2026 vs. Q2 2025: €1,561m vs. €1,466m (higher year on year)
    • Net Loss, Q2 2026 vs. Q2 2025: €53m loss vs. €45m loss (loss widened year on year)
    • Basic EPS, Q2 2026 vs. Q2 2025: €0.62 loss per share vs. €0.52 loss per share (per share loss increased year on year)
    • Trailing 12-month Net Loss, Q2 2026 vs. Q2 2025: €669m loss vs. €165m loss (very large increase in trailing loss)

    Prefer clear charts over a dense wall of earnings figures and ratios? View LANXESS' complete financial picture, including a visual overview of its recent earnings performance and income statement trends, in our company report for LANXESS.

    XTRA:LXS Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    XTRA:LXS Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Evaluating LANXESS’ Transformation Milestones Against Q2 Results

    The bullish story around LANXESS is that cost cuts, portfolio reshaping and process upgrades will steadily lift margins and cash generation in its specialty businesses. Q2 gives some concrete progress on that score. Management kept full year EBITDA guidance intact and pointed to strong free cash flow in a quarter that is usually less cash generative. That lines up with the promise of tighter working capital and SG&A discipline.

    The narrative also leans on specialty exposure. Specialty Additives and Consumer Protection both contributed positively in Q2 and are expected to support the second half, which is consistent with a shift toward higher value segments. Early cost measures are visible, with 214 fewer employees since the end of 2025 and a €65m savings target for 2026. However, group utilization below 70% and a wider net loss show that the transformation is still working against a heavy earnings drag from underused, energy intensive assets.

    Reveal where the surface looks calm but the multi year models for LANXESS start to diverge, and see what the street is secretly modeling for the next FY and beyond with the detailed analyst estimates for LANXESS.

    LANXESS Bears Still See More Questions Than Answers

    The bearish view on LANXESS is that structurally weak, energy intensive intermediates, soft end markets and execution risk on restructuring will keep losses and cash pressure in play for longer than bulls hope. Q2 does not fully disarm that case. Revenue inched higher but the quarterly net loss widened to €53m and basic loss per share deepened to €0.62. The trailing 12 month net loss expanded sharply to €669m. That is a clear miss versus any hope that cost cutting would already show up in cleaner earnings.

    Bears worry that higher European energy costs and low utilization will cap margins. Management confirmed utilization below 70% and pointed to ongoing energy headwinds in Advanced Intermediates and pigments. Cost savings are progressing but not yet quantified in detail, and restructuring of Saltigo is still at an early stage. Against those concerns, this print looks more like partial progress than a turning point.

    With LANXESS still loss making and losses having grown at an annualized 48% rate over five years, the key question is how much balance sheet capacity really remains to fund this turnaround. Check the real liquidity, leverage and cash runway story in the financial health analysis of LANXESS stock.

    Stay Ahead With LANXESS Insights

    If the mix of ongoing losses and restructuring progress at LANXESS has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the turnaround story develops. Once you are invested, use the Portfolio Command Center to cut through the noise and focus on the updates that matter most for your holdings. For longer term context and fresh angles, tap into thousands of investor views through the Community. By surfacing hidden catalysts and risks early, you give yourself a better shot at staying ahead of the market.

    Seeking Alternatives Beyond LANXESS?

    Fresh breakout ideas rarely stay under the radar for long. Before momentum is fully caught by the crowd and prices start flying or dropping, scan these curated picks and consider your options early.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.